Valuation: EnteroMedics Inc

Market Cap 14.32M 12.56M 11.87M 10.81M 20.24M 1.37B 20.39M 142M 55M 701M 53.76M 52.59M 2.25B P/E 2026 *
-3.74x
P/E 2027 * -2.55x
Enterprise Value 14.32M 12.56M 11.87M 10.81M 20.24M 1.37B 20.39M 142M 55M 701M 53.76M 52.59M 2.25B EV / Sales 2026 *
131x
EV / Sales 2027 * 71.6x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 110K 96.09K 90.75K 82.7K 155K 10.49M 156K 1.09M 421K 5.36M 411K 402K 17.23M 200K 176K 166K 151K 283K 19.17M 285K 1.98M 768K 9.79M 751K 735K 31.47M
Net income -3.8M -3.33M -3.15M -2.87M -5.37M -364M -5.41M -37.69M -14.6M -186M -14.27M -13.96M -598M -7.85M -6.88M -6.5M -5.93M -11.09M -752M -11.17M -77.81M -30.14M -384M -29.46M -28.82M -1.23B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-